NASDAQ · OABI
Healthcare · Biotechnology
$4.61
Down-$0.19 (-4.01%)
Updated Aug 28, 2026, 6:23 PM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
OABI closed at $4.61 after 21 trading sessions, up 131.66% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 27, 2026 | $4.81 | $4.81 | $4.56 | $4.61 | 1.28M |
| Aug 26, 2026 | $4.695 | $4.93 | $4.635 | $4.81 | 1.44M |
| Aug 25, 2026 | $4.68 | $4.78 | $4.58 | $4.66 | 1.47M |
| Aug 24, 2026 | $4.40 | $4.71 | $4.20 | $4.71 | 1.94M |
| Aug 21, 2026 | $4.31 | $4.535 | $4.14 | $4.33 | 1.85M |
| Aug 20, 2026 | $4.188 | $4.59 | $4.16 | $4.30 | 2.25M |
| Aug 19, 2026 | $3.95 | $4.19 | $3.83 | $4.19 | 2.87M |
| Aug 18, 2026 | $3.84 | $4.19 | $3.7892 | $3.92 | 3.25M |
| Aug 17, 2026 | $4.185 | $4.2899 | $3.715 | $3.82 | 18.35M |
| Aug 14, 2026 | $3.40 | $3.45 | $3.30 | $3.38 | 554.42K |
| Aug 13, 2026 | $3.44 | $3.635 | $3.41 | $3.43 | 922.41K |
| Aug 12, 2026 | $3.39 | $3.49 | $3.34 | $3.42 | 794.03K |
| Aug 11, 2026 | $3.33 | $3.545 | $3.295 | $3.38 | 1.19M |
| Aug 10, 2026 | $3.14 | $3.435 | $2.99 | $3.39 | 1.84M |
| Aug 7, 2026 | $2.37 | $3.12 | $2.352 | $3.08 | 2.68M |
| Aug 6, 2026 | $2.04 | $2.27 | $2.04 | $2.24 | 702.75K |
| Aug 5, 2026 | $2.01 | $2.10 | $1.98 | $2.03 | 441.84K |
| Aug 4, 2026 | $1.96 | $2.035 | $1.94 | $2.00 | 352.54K |
| Aug 3, 2026 | $2.01 | $2.01 | $1.945 | $1.96 | 228.58K |
| Jul 31, 2026 | $1.99 | $2.04 | $1.90 | $1.98 | 275.28K |
| Jul 30, 2026 | $1.95 | $2.019 | $1.95 | $1.99 | 204.3K |
The latest Smart Investors Daily articles mentioning OABI.
OABI research
Company profile and research snapshot.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2025 | RBC Capital | Outperform | — |
| May 12, 2025 | Benchmark | Buy | — |
| Mar 27, 2025 | RBC Capital | Outperform | — |
| Mar 20, 2025 | Benchmark | Buy | — |
No generated briefing is available yet.
ChartMill · Aug 22, 2026
OmniAb (OABI) passes Minervini's trend template with strong momentum and accelerating growth, but a low setup rating suggests waiting for a pullback.
SeekingAlpha · Aug 18, 2026
OmniAb (OABI) analysis: platform scaling via Eli Lilly partnership, milestone-rich revenue outlook, 2026 cash guidance, valuation and catalystsâread now.
Benzinga · Aug 17, 2026
HC Wainwright & Co. analyst Joseph Pantginis reiterates OmniAb (NASDAQ:OABI) with a Buy and maintains $11 price target.
Benzinga · Aug 17, 2026
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning OABI.
